Susana Campos, MD, MPH
Enriched profileClinical Director and Director of Educational Initiatives, Division of Gynecologic Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Susana Campos is Clinical Director and Director of Educational Initiatives, Division of Gynecologic Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 167 publications with 9,571 citations (h-index 45); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 21 Oct 2026
Susana Campos, MD MPH, is Clinical Director and Director of Educational Initiatives, Division of Gynecologic Oncology, Dana-Farber Cancer Institute. The public record shows 167 publications with 9,571 citations (h-index 45), centered on Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2025 · medRxiv
- Top research focus: Endometrial and Cervical Cancer Treatments
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 79.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Tivozanib As Maintenance Therapy In GYN
Sponsor: Dana-Farber Cancer Institute
- Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 21 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20256 payments$17,067openpaymentsdata.cms.gov ↗
- Genmab U.S., Inc.Program year202522 payments$14,816openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Anastrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 21 Oct 2026
31 congress contributions (2004–2025) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
International journal of clinical oncology
Clinical Trial2022 - A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.
Cancer chemotherapy and pharmacology
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)- 01Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyArticle1,054 citations2019
- 02Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyArticle643 citations2018
- 03
- 04Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in OncologyArticle568 citations2023
- 05NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024Article384 citations2023
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/susana-campos-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Member
National Comprehensive Cancer Network Uterine Cancer Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Member
Gynecology Oncology Group Corpus Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Previous Chair
American Society of Clinical Oncology Gynecological Education Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Harvard Medical School
Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- OncLive On Air podcast appearance
November 21, 2024, discussing trastuzumab deruxtecan in gynecologic cancers and adverse effect management
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Frank Hodi, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute